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ABSTRACT
Objectives: The primary objective was to measure HIV
incidence in two prospective cohorts of HIV-negative
women. Secondary objectives included measuring
pregnancy rates and participant retention rates.
Design: Cross-sectional HIV screening of women
selected for higher risk behaviours, with a subsequent
prospective study of uninfected women, followed
monthly for up to 6 months.
Setting: Clinics established for research purposes in
Bloemfontein and Rustenburg, South Africa.
Participants: The authors enrolled women
18e35 years old and presumed at higher risk of sexual
acquisition of HIV as indicated by self-reported sexual
behaviour or recent sexually transmitted infection
symptoms. In Bloemfontein, 1364 women were
screened, 1154 were eligible for HIV testing and 1145
agreed to be tested. The prospective study enrolled
401 HIV-negative women. In Rustenburg, 946 women
were screened, 540 were eligible and underwent HIV
testing and 223 HIV-negative women entered the
prospective study.
Primary and secondary outcomes: Baseline
prevalences of HIV infection and HIV incidence rates in
the prospective cohorts, according to a double rapid
test algorithm with a third rapid test for discrepant or
indeterminate results. Pregnancy prevalences and
pregnancy incidence rate in Bloemfontein.
Participant retention rates in the prospective cohort
until the study end.
Results: In Bloemfontein, 1145 women were tested,
391 entered follow-up and 92.3% of participants
completed six study visits. In Rustenburg, 540
women were tested, 194 entered follow-up and
retention up to the point of early study termination was
88.6%. Overall HIV prevalence was 21.2% (95% CI
18.9% to 23.6%) in Bloemfontein and 23.5% (95% CI
19.9% to 27.1%) in Rustenburg. Overall HIV incidence
was 5.5/100 person-years (95% CI 2.5 to 10.4) in
Bloemfontein and 3.0/100 person-years (95% CI 0.4 to
10.8) in Rustenburg. Cross-sectional pregnancy
prevalences were 6.5% in Bloemfontein and 8.6% in
Rustenburg.
ARTICLE SUMMARY
Article focus
- Primary objective: measure HIV incidence and
prevalence among women in two prospective
cohorts selected for higher risk behaviours.
- Secondary objective 1: measure pregnancy rates.
- Secondary objective 2: measure retention rates.
Key messages
- We measured the HIV burden among women
selected to be at higher risk in two smaller South
African cities, while training new clinical research
groups there.
- HIV seroprevalence was 21.2% in Bloemfontein
and 23.5% in Rustenburg.
- HIV incidence rates were 5.5/100 person-years in
Bloemfontein and 3.0/100 person-years in
Rustenburg.
Study strengths
- Longitudinal design with high retention rates.
- Highly accurate classiﬁcation of the HIV
outcome, using multiple rapid tests monthly,
conﬁrmed by later PCR testing.
- Testing of stored baseline specimens to pinpoint
seroconversion and rule out acute prestudy
infections.
- Direct prospective measurement of HIV infection
circumvented the lingering issues with the
accuracy of cross-sectional incidence estimation.
Study limitations
- Unknown validity of self-reported sexual
behaviours.
- Relatively small study size precluded multivari-
able Cox regression analysis.
- Selective recruitment means that the prevalence
and incidence ﬁgures are not representative of
women in these two cities.
- The lack of sexually transmitted infection diag-
nostic testing precluded evaluating associations
between HIV and other infections.
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Open Access ResearchConclusions: The authors observed substantial HIV incidence rates
in both cohorts. Vigorous prevention efforts are needed in these
smaller cities.
INTRODUCTION
HIV/AIDS continues to exact a massive toll on the
health, economics and political infrastructure of
communities around the world. In sub-Saharan Africa,
the most heavily affected region, an estimated 22.4
million people were reported to be living with HIV in
2008.
1 While recent prevention trials assessing male
circumcision, antiretroviral gel use and pre-exposure
prophylaxis have shown signiﬁcant promise,
2e5 studies
to corroborate these results and to evaluate new
prevention methods will be required. To meet the
ongoing need for research sites in countries with
substantial HIV burden, FHI 360’s Site Identiﬁcation
and Development Initiative (SIDI) undertook the
development of previous research naive sites in six
countries to conduct future HIV prevention research.
The SIDI team partnered with groups in two South
African cities for clinical research development: Bloem-
fontein in the Motheo District of Free State Province and
Rustenburg in the Bojanala District of Northwest Prov-
ince. District-level HIV prevalence rates among antenatal
women aged 15e49 years were 27.8% and 34.9%,
respectively, in 2009; provincial HIV prevalence rates
were 30.1% (Free State) and 30% (Northwest).
6 HIV
incidence rates for both sites had not been measured.
The goal of the SIDI project was to develop HIV
prevention research capacity and to determine the suit-
ability of each site to implement future HIV prevention
clinical trials. Each site conducted its own prevalence
and incidence study using a similar protocol. The
primary objective of each study was to measure HIV
incidence in a prospective cohort of HIV-negative
women at each study site. Secondary objectives included
measuring pregnancy rates and participant accrual and
retention rates in the cohort.
METHODS
Study design and recruitment
The study comprised cross-sectional screening with HIV
testing, followed by a prospective cohort study with up to
six monthly follow-up visits. In Bloemfontein, the study
was conducted at the JOSHA Research Centre. Bloem-
fontein and the surrounding Mangaung municipality
comprise a population of approximately 600000 people.
JOSHA is an independent clinical research facility that
can draw participants from afﬁliated general practices as
well as from cooperating government clinics. Partici-
pants for the cross-sectional screening were recruited
using methods developed based on the feedback from
community engagement activities led by the Mangaung-
University Community Partnership Program (MUCPP)
and input from key stakeholders in the community.
Recruitment methods included (1) recruitment from
HIV counselling and testing, sexually transmitted disease
and family planning clinics; (2) targeted outreach
activities in the community and (3) referrals from other
clinics. Participants for the prospective study were
recruited from among the HIV-negative participants in
cross-sectional screening.
In Rustenburg, with a population estimated at 350000
in the 2001 census but which has grown considerably
since then, the study was conducted at The Aurum
Institute’s Rustenburg Research Centre located down-
town. The Rustenburg economy is largely driven by the
platinum mining industry and is home to a large, diverse
and growing inﬂux of residents attracted to the area for
work in the mining industry. The Aurum Institute
(formerly the Aurum Institute for Health Research) is
a non-proﬁt research organisation that began activities
in March 2007 to prepare the Rustenburg Municipality
to engage in epidemiologic studies and future clinical
research trials. Participants for the cross-sectional
screening were recruited from a variety of clinic-based
and community settings, which included an emphasis on
local colleges. To facilitate recruitment and enrolment
for cross-sectional screening, the protocol was amended
twice late in the study to add respondent-driven
sampling for recruitment (not inference) purposes
7 and
to liberalise the sexual behaviour eligibility criterion.
Both men and women were recruited for cross-sectional
screening in Rustenburg, but only HIV-negative women
were invited to participate in the prospective study as
there was a separate male cohort study there.
Study procedures
Following the informed consent process and assignment
of a participant number, volunteers were considered
enrolled. Enrolled participants were screened for eligi-
bility for cross-sectional testing using a demographic and
HIV risk factor questionnaire. Recruitment and
screening staff at both sites were blind to the speciﬁc
behavioural eligibility criteria to avoid the spread of
information through the community and to prevent
volunteers from altering self-reported behaviours to gain
access to the study. All participants were asked the full
questionnaire regardless of their initial answers.
Only eligible women were tested. Eligibility for HIV
and pregnancy testing was determined by age (18e35 at
the time of screening) and presumed higher risk of
sexual acquisition of HIVas deﬁned by at least one of the
following self-reported criteria in the past 3 months:
(1) treatment for, diagnosis of or signs/symptoms of
a sexually transmitted infection (STI); (2) vaginal or
anal intercourse with more than one partner (unpro-
tected intercourse in Rustenburg only); (3) vaginal or
anal intercourse with a new sexual partner (unprotected
intercourse in Rustenburg only) or (4) sex with an HIV-
infected partner who is not using antiretroviral therapy.
Near the end of the Rustenburg study, we revised these
criteria to remove the requirements for multiple part-
ners and unprotected sexual acts for women, as we
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HIV incidence in two South African cohortssuspected that we were screening out many higher risk
women and that condom use reporting was not accurate.
Participants deemed eligible underwent HIV testing
within the context of HIV pretest and post-test counsel-
ling in accordance with national guidelines. Women also
had urine pregnancy tests. Results of both tests were
provided to participants during their visits.
Women were eligible to enter the prospective cohort
study if they met the cross-sectional age and behavioural
criteria, were HIV negative and pregnancy negative and
were not planning to relocate from the area in the near
future. The target prospective study size was the ﬁrst 400
eligible women at each site, followed monthly for up to
6 months. At each monthly visit, participants provided
updated medical and behavioural information, under-
went HIV and pregnancy testing, received syndromic
management for STIs (as needed), were counselled on
HIV risk reduction practices and received free condoms.
HIV testing was performed on ﬁnger prick blood
samples using a double rapid test algorithm with the
Abbott Determine HIVd1/2 and Trinity Biotech Uni-
Gold run in parallel. Two positive results were deemed
positive and two negative results were deemed negative,
which exceeded national HIV testing guidelines.
Discrepant or indeterminate samples were tested with
a third rapid test, SD BIOLINE HIVd1/2 3.0, as a tie-
breaker. Pregnancy testing was performed on urine
samples using the Quidel QuickVue hCG-Combo test.
All tests were run according to the manufacturers’
speciﬁcations.
Participants who tested HIV positive at screening or
during the cohort study were referred for care in
accordance with local guidelines. In addition, those
participants who seroconverted during the prospective
phase were intensely counselled about secondary HIV
prevention in the acute infection period and in
Rustenburg were invited to join a seroconvertor cohort
with continued close monitoring. Participants who were
found to be pregnant were referred for antenatal care.
Participants who became pregnant during follow-up
continued to make study visits.
Ethical considerations
The protocols, informed consent forms, participant
education and recruitment materials, case report forms
and compensation amount for visits (50 rand) were
reviewed and approved by the FHI 360 ethics committee
and the local ethics committees, the University of Free
State ethics committee for Bloemfontein and the
University of KwaZulu Natal Biomedical Research Ethics
Committee for Rustenburg.
We obtained written informed consent from each
participant prior to enrolment and data collection.
Written consent was also obtained for long-term spec-
imen storage and possible future testing, although
consent for specimen storage was not required for study
participation. Informed consent forms were available in
English and were translated into local languages,
Sesotho (Bloemfontein) and Sestwana and IsiXhosa
(Rustenburg), to enhance comprehension. Volunteers
had their choice of language for the informed consent
process, which was witnessed and veriﬁed by a non-study
staff person for illiterate or low-literate participants.
Statistical analysis
All eligible participants were included in the data anal-
ysis. For each site, we summarised participants’ socio-
demographic characteristics, self-reported STI symptoms
and HIV risk behaviours at baseline for cross-sectional
screening participants and those women who entered
the prospective study. We calculated baseline prevalences
of HIV infection and pregnancy among women, along
with 95% CIs. We used univariate and multivariable
logistic regression analysis to evaluate the association
between risk factors and prevalent HIV infection.
The incidence rate was calculated as the number of
post-enrolment HIV seroconversions divided by the
person-years (PY) of observation accumulated by the
cohort. We calculated 95% CI using exact methods
under the assumption that the number of HIV infections
follows a Poisson distribution. We used proportional
hazards regression to evaluate the associations between
incident HIV infection and possible HIV risk factors
including time-dependent participant characteristics
and time-varying risk behaviours and self-reported STI
symptoms. Due to the small number of HIV serocon-
versions, we did univariate proportional hazards regres-
sion only. Data analyses were performed using SAS V.9.2.
RESULTS
Eligible populations
In Bloemfontein, the cross-sectional screening enrolled
1364 women between February and October 2009. Of the
1364 enrolled women, 1154 were determined to be
eligible for testing and 1145 (84% of enrollees) chose to
be tested in cross-sectional screening. Virtually all of the
women who were screened out from cross-sectional
testing failed to satisfy the behavioural or STI risk criteria.
The prospective study enrolled 401 HIV-negative women
volunteers from screening. Of those 401 women, 399
were determined to be eligible and 391 entered follow-
up and were tested. 92.3% of participants completed
six study visits, for a median 5.6 person-months of
observation and a total 164.4 PY.
In Rustenburg, cross-sectional screening enrolled 946
women and 968 men between November 2008 and
December 2009. Data on the male participants are not
presented here. Of the 946 enrolled women, 540 (57%)
were eligible and underwent testing in cross-sectional
screening; virtually all of the women who were screened
out from cross-sectional testing did not satisfy the
behavioural or STI risk criteria. The prospective study
enrolled 223 HIV-negative women volunteers, of whom
194 yielded HIV test data. In Rustenburg, many women
screened out from the prospective study due to plans to
re-locate. Completion of follow-up in the prospective
study was hindered when it was ended prematurely due
to funding shortfalls, but retention in follow-up up to the
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person-months of observation and a total 67.1 PY.
Participant characteristics
Large percentages of participants in cross-sectional
screening at both sites were #21 years, had a high school-
level education, were not employed, were unmarried and
lived with family members (table 1). About one-third of
the women were using an effective contraceptive at each
site (hormonal method or IUCD: 38.3% in Bloemfontein
and 32.9% in Rustenburg; table 1). STI testing was not
done; self-reported STI signs/symptoms at baseline
ranged from 2% to 15% prevalence in Bloemfontein and
from 22% to 37% in Rustenburg.
Table 1 Participant features (N (%)) of eligible women at inception of cross-sectional screening and prospective study in
Bloemfontein and Rustenburg sites
Bloemfontein Rustenburg
Cross-sectional,
N[1154
Prospective,
N[399
Cross-sectional,
N[540
Prospective,
N[223
Age
<21 520 (45.1) 206 (51.6) 239 (44.2) 115 (51.6)
22e24 259 (22.4) 92 (23.1) 130 (24.1) 53 (23.8)
25e31 284 (24.6) 76 (19.1) 138 (25.6) 46 (20.6)
>31 91 (7.9) 25 (6.3) 33 (6.1) 9 (4.0)
Education
Nonedgrade 5 32 (2.8) 7 (1.8) 4 (0.8) 0 (0.0)
Grades 6e9 181 (15.7) 49 (12.3) 27 (5.0) 10 (4.5)
Grades 10e12 860 (74.5) 333 (83.5) 454 (84.1) 188 (84.3)
University/college/graduate 81 (7.0) 10 (2.5) 55 (10.2) 25 (11.2)
Employment
No, unemployed 1000 (86.7) 352 (88.2) 463 (85.7) 196 (87.9)
Yes, part time 78 (6.8) 25 (6.3) 31 (5.7) 11 (4.9)
Yes, full time 76 (6.6) 22 (5.5) 46 (8.5) 16 (7.2)
Whom you live with
Alone 45 (3.9) 12 (3.0) 25 (4.6) 8 (3.6)
Spouse 52 (4.5) 15 (3.8) 15 (2.8) 8 (3.6)
Family/relatives 859 (74.4) 315 (78.9) 375 (69.4) 160 (71.8)
Roommate/friend 103 (8.9) 34 (8.5) 28 (5.2) 12 (5.4)
Partner 95 (8.2) 23 (5.8) 97 (18.0) 35 (15.7)
Married
No 1056 (91.5) 369 (92.5) 507 (93.9) 211 (94.6)
Yes 98 (8.5) 30 (7.5) 33 (6.1) 12 (5.4)
Contraceptive use
None 540 (46.9) 182 (45.6) 157 (29.1) 58 (26.0)
Oral 55 (4.8) 20 (5.0) 24 (4.4) 19 (8.5)
Injectable 384 (33.3) 138 (34.6) 132 (24.4) 65 (29.2)
IUCD 2 (0.2) 0 (0.0) 1 (0.2) 1 (0.5)
Condoms 148 (12.9) 52 (13.0) 201 (37.2) 80 (35.9)
Other 23 (2.0) 7 (1.8) 1 (0.2) 0 (0.0)
Missing 2 (0.2) 0 (0.0) 24 (4.4) 0 (0.0)
STI signs/symptoms
Vaginal discharge 155 (13.4) 52 (13.0) 154 (28.5) 59 (26.5)
Painful urination 103 (8.9) 31 (7.8) 153 (28.3) 57 (25.6)
Lower abdominal pain 115 (10.0) 39 (9.8) 202 (37.4) 82 (36.8)
Vaginal itching 170 (14.7) 60 (15.0) 155 (28.7) 63 (28.5)
Dyspareunia 104 (9.0) 35 (8.8) 121 (22.4) 50 (22.4)
Vaginal sore 27 (2.3) 12 (3.0) 142 (26.3) 66 (29.6)
No. of sex partners in last month
0 53 (4.6) 18 (4.5) 85 (15.7) 40 (17.9)
1 362 (31.4) 120 (30.1) 400 (74.1) 155 (69.5)
2+ 739 (64.0) 261 (65.4) 55 (10.2) 28 (12.6)
Vaginal sex w/o condom past
week w primary partner
638 (55.3) 202 (50.6) 190 (35.2) 78 (35.0)
Vaginal sex w/o condom past
week w other partner
150 (13.0) 50 (12.5) 8 (1.5) 3 (1.3)
STI, sexually transmitted infection; w, with; w/o, without.
4 Feldblum PJ, Latka MH, Lombaard J, et al. BMJ Open 2012;2:e000626. doi:10.1136/bmjopen-2011-000626
HIV incidence in two South African cohortsAt baseline, women in the Bloemfontein study self-
reported more risk behaviours than women in Rusten-
burg (table 1). Two-thirds of women in Bloemfontein
reported vaginal intercourse with two or more partners
in the month preceding cross-sectional screening; the
corresponding percentage in Rustenburg was 14%. Over
half of the women in Bloemfontein reported having
vaginal intercourse with their primary partners without
a condom in the previous week, whereas about a quarter
of women in Rustenburg reported unprotected inter-
course with primary partners in the previous week.
Women in Bloemfontein were also more likely to report
unprotected intercourse with a non-primary partner.
The baseline features of women who entered the
prospective studies were broadly similar to those of the
source screening populations at both sites (table 1), and
there was little indication of selection for a particular
subgroup into the prospective cohort.
HIV prevalence
In Bloemfontein cross-sectional screening, the HIV
prevalence was 21.2% (95% CI 18.9% to 23.6%), overall:
13.4% in those 18e24 years, 38.1% in those 25e29 years
and 37.1% in women aged 30e35 years (table 2). In
Rustenburg, the overall HIV prevalence at screening was
23.5% (95% CI 19.9% to 27.1%) among women, ranging
from 18.7% in those aged 18e24 years to 31.8% in those
aged 25e29 years to 37.7% in those aged 30e35 years
(table 2).
Factors associated with prevalent HIV
Three baseline factors were signiﬁcantly associated with
prevalent HIV infection at both study sites (table 3): age
30 or older compared with 18e24, less versus more
educational attainment and living with a child versus not
living with child. Self-reported signs or symptoms of
STI were associated with HIV in Bloemfontein only, and
non-use of contraception versus use of condoms was
associated with HIV in Rustenburg only. Sexual behav-
iour factors were not signiﬁcantly associated with preva-
lent HIV infection.
HIV incidence
Nine seroconversions were observed during the
prospective study in the Bloemfontein cohort, an overall
incidence of 5.5/100 PY (95% CI 2.5 to 10.4; table 4).
The incidence was 5.7/100 PY (95% CI 2.3 to 11.7) in
women 18e24 years, 4.2/100 PY (95% CI 0.1 to 23.5)
among women 25e29 years and 5.8/100 PY (95% CI 0.2
to 32.2) in the sparse 30e35 years age stratum.
Two seroconversions were detected in the Rustenburg
cohort for an overall incidence of 3.0/100 PY (95% CI
0.4 to 10.8; table 4). Both seroconversions were in the
18e24 year age group, and the incidence in that
younger age range was 4.0/100 PY (95% CI 0.5 to 14.5).
Ten of the 11 incident HIV infections at the two sites
clearly occurred after enrolment in the prospective
phase. One seroconversion in Bloemfontein was more
problematic; rapid tests were negative at cross-sectional
testing and no virus was detected in that stored specimen
by PCR, but Western blot results were positive for the
stored baseline specimen and were persistently blot
positive until seroconversion at the 3-month visit. After
excluding that Bloemfontein participant, the re-calcu-
lated Bloemfontein incidence rate was 4.9/100 PY (95%
CI 2.1 to 9.6).
Factors associated with incident HIV
With nine new infections in the Bloemfontein cohort, we
performed univariate proportional hazards regression
with the same factors included in the analysis of risk
factors for prevalent infection (above). No factor was
signiﬁcantly associated with incident infection. The
strongest association with incident HIV was found for
Table 2 HIV prevalence among women in cross-sectional screening by age group and research site
Bloemfontein Rustenburg
Age 18e24
Eligible population*, N 776 369
HIV positive, N 104 69
Prevalence (95% CIy) 13.4% (11.0% to 15.8%) 18.7% (14.7% to 22.7%)
Age 25e29
Eligible population*, N 226 110
HIV positive, N 86 35
Prevalence (95% CIy) 38.1% (31.7% to 44.4%) 31.8% (23.1% to 40.5%)
Age 30+
Eligible population*, N 143 61
HIV positive, N 53 23
Prevalence (95% CIy) 37.1% (29.1% to 45.0%) 37.7% (25.5% to 49.9%)
Total
Eligible population*, N 1145 540
HIV positive, N 243 127
Prevalence (95% CIy) 21.2% (18.9% to 23.6%) 23.5% (19.9% to 27.1%)
*Eligible and had HIV test result.
yApproximate CI.
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partner in the last month (HR¼6.7; p¼0.07).
Pregnancy
The prevalence of pregnancy at the time of cross-
sectional screening was 6.5% (95% CI 5.0% to 7.9%) in
Bloemfontein and 8.6% (95% CI 6.2% to 10.9%) in
Rustenburg. (Further analysis of the Rustenburg preg-
nancy results will appear elsewhere.) In Bloemfontein,
the pregnancy prevalence in screened women ranged
from 11.0% (95% CI 8.5% to 14.0%) in those not using
a method to 3.5% (95% CI 1.3% to 7.5%) in condom
users and 2.1% (95% CI 0.9% to 3.9%) in users of
effective methods (hormonal and IUCDs). The Bloem-
fontein pregnancy incidence was 16.4/100 PY (95% CI
10.8 to 23.9) and ranged from 27.6/100 PY (95% CI 17.1
to 42.2) in women not using a method at baseline to
12.4/100 (95% CI 2.6 to 36.4) in condom users and 4.7/
100 (95% CI 1.0 to 13.7) in users of effective methods
(hormonal or IUCD).
DISCUSSION
HIV prevalence in Bloemfontein’s Free State Province
has been close to 30% in antenatal surveillance for
several years. Prevalence was lower in this study, at
21.2%, yet we detected a high incidence rate of 5.5/100
PY in the overall cohort. We observed similar HIV inci-
dence across the age spectrum in the Bloemfontein
cohort, contrary to national estimates.
8 The HIV preva-
lence among Rustenburg women in the cross-sectional
screening was 23.5%, again lower than recent antenatal
surveillance data from the area, which could be
explained by the young average age of the cohort
screened. The prospective incidence rate in the
Rustenburg cohort was 3.0/100 PY and higher among
younger women (4.0/100 PY in 18e24 year olds).
National household survey data in South Africa show
that HIV prevalence has stabilised and suggest that the
incidence estimated from nationally representative
surveys has declined in younger age groups.
8 But the
overall estimated incidence remained 1.3/100 unin-
fected persons of reproductive age from 2005 to 2008.
8
Others have described a pattern of stable prevalence in
South African antenatal surveillance and population-
based surveys coupled with substantial incidence rates in
deﬁned cohorts.
9 In the relatively few studies that have
directly measured HIV incidence, it has been distress-
ingly high in both urban and rural sites, despite multiple
follow-up contacts, ongoing risk-reduction counselling
and condom promotion and provision. Between 2001
and 2004, a representative cohort in one part of rural
Limpopo Province had an HIV incidence of 4.9/100 PY
among women, despite self-reported increases in
condom use during that period.
10 In the HPTN 055
cohort study, the two South African sites, both located in
Kwa-Zulu Natal Province, had the highest HIV incidence
rates in 2003e2004 (Durban 5.3/100 PY and Hlabisa
6.2/100 PY).
11 In 2004e2007, the HIV incidence rate
was 6.4/100 PY and 6.5/100 PY in an urban and a rural
cohort in KwaZulu-Natal, respectively.
9 Three recent
randomised trials of ineffective prevention products
have also reported substantial HIV incidence at their
South African sites.
12e14 Finally, a cohort study
conducted between 2007 and 2009 at two sites in
Northwest Province and Western Cape Province for
capacity-building purposes reported 12-month incidence
rates of 6.0/100 PY and 4.5/100 PY, similar to the rates
reported here.
15
Older participants had a higher risk of prevalent HIV
infection in our study than younger, reﬂecting their
longer potential for exposure to HIV. Lesser education
was also associated with baseline HIV infection, as has
Table 3 Multivariable logistic regression analysis of factors associated with prevalent HIV among women screened in
Bloemfontein and Rustenburg, South Africa
Factor
Bloemfontein Rustenburg
OR (95% CI) OR (95% CI)
Age 18e24 vs 30+ 0.389 (0.243 to 0.623) 0.485 (0.284 to 0.826)
Age 24e29 vs 30+ 1.222 (0.766 to 1.950) 0.844 (0.502 to 1.419)
Education: less than high school 2.240 (1.552 to 3.233) 1.979 (1.099 to 3.563)
Employed: yes 0.913 (0.587 to 1.419) 0.790 (0.509 to 1.227)
Living with child 1.569 (1.074 to 2.290) 2.078 (1.398 to 3.088)
Married 0.900 (0.541 to 1.498) 0.664 (0.304 to 1.450)
STI sign/symptom 2.081 (1.472 to 2.940) 1.071 (0.729 to 1.573)
Contraception: no method vs condom/other 1.395 (0.874 to 2.229) 2.056 (1.319 to 3.203)
Contraception: effective vs condom/other 0.777 (0.474 to 1.273) 1.321 (0.827 to 2.111)
More than 1 partner 1.250 (0.594 to 2.632) 1.425 (0.863 to 2.354)
1 or more new partner 1.168 (0.853 to 1.598) 1.136 (0.724 to 1.783)
More than 1 different partner 0.809 (0.564 to 1.161) 0.836 (0.504 to 1.387)
1 or more sex without condom with primary partner last month 1.279 (0.917 to 1.786) 1.165 (0.776 to 1.748)
1 or more sex without condom with any other partner last month 1.067 (0.622 to 1.831) 1.224 (0.444 to 3.379)
Anal sex with primary partner 0.828 (0.407 to 1.686) 0.974 (0.318 to 2.984)
Anal sex with any other partner 0.660 (0.183 to 2.383) 1.333 (0.153 to 11.577)
Signiﬁcant factors are in bold-face.
STI, sexually transmitted infection.
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10 16 Other
factors were not consistently associated with baseline
infection across the sites, which may stem from unmea-
sured sexual network factors and misclassiﬁcation error
resulting from self-report. In fact, the striking differ-
ences in the self-reported risk behaviours between these
two cohorts suggest that some self-reporting bias may
have occurred. Bloemfontein participants reported high
rates of multiple partnering (about two-thirds of the
women) compared with national data on South African
women aged 15e49 years (3.7% in 2008) and data on
men and women in the Free State in the same 2008
survey (14.6%).
17 In contrast, reports of multiple part-
nering at the Rustenburg site were close to national
averages (12%e14%) and similar to a prior representa-
tive household survey in Rustenburg.
18
One weakness of our analysis is that, partly due to the
relatively short follow-up period, there were too few
seroconversion events to do multivariable proportional
hazards regression, and our univariate regression results
for incident HIV infections were necessarily inconclu-
sive. A limitation of the analysis of risk factors for prev-
alent HIV infections is that the behaviours reported at
screening may not have reﬂected behaviours present at
the time of infection. Lack of STI diagnostic testing
precluded evaluating associations with other infections.
Perhaps the greatest study weakness relates to the
validity of self-reported sexual behaviours, both for
purposes of determining eligibility as well as for assessing
risk during follow-up. The inaccuracies in self-reported
sexual behaviour during research interviews have been
amply documented and are not unique to these studies.
Although we attempted to keep the eligibility factors
secret from participants and outreach staff, we do not
know if volunteers (both eligible and ineligible) guessed
those factors and shared them with other women in the
community. There may have been an awareness among
women at the Bloemfontein site in particular to over-
report risky behaviours to gain entry to the study: the
eligibility rate was very high there and risk behaviours far
exceeded national estimates. Alternatively, recruiters at
the Bloemfontein, but not the Rustenburg, site may have
simply tapped into a subgroup of women with particu-
larly risky behaviour. During baseline and follow-up
interviews with participants, however, we did not observe
strong associations between those same behavioural
factors and HIV infection.
Our study cohorts cannot be considered representa-
tive of young women in the two cities. Our behavioural
eligibility criteria selected for a group of women with
higher than average risk behaviours. The Rustenburg
site offered the opportunity to demonstrate the impact
of these selection factors: a representative household
survey had been done there in 2008, 1 year before our
study commenced. Our study cohort was younger, better
educated, less likely to be employed and less likely to be
married or live with a steady partner than all Rustenburg
community residents. Most critically, only 3.4% of
women in the household survey reported multiple
sexual partners in the past 3 months compared with over
10% of women screened in our study who reported
multiple partners in the past 1 month. So we make no
claims for representativeness: our project deliberately set
out to identify and follow a cohort with higher than
average risk behaviours, in order to demonstrate the
suitability of the sites for future prevention research.
Countervailing study strengths include the longitu-
dinal design with high retention rates. Classiﬁcation of
the HIV outcome was highly accurate, using multiple
monthly rapid tests conﬁrmed by later PCR testing.
Testing of stored baseline specimens allowed us to
pinpoint seroconversion and rule out acute prestudy
infections. Finally, direct prospective measurement of
HIV infection circumvented the lingering issues with the
accuracy of cross-sectional incidence estimation.
The high HIV prevalences and incidence rates in these
cohorts in two smaller South African cities should spur
vigorous HIV prevention efforts. The need for HIV care
and treatment in these areas is clear, and while care is
available, Free State Province experienced stock-outs of
HIV antiretroviral drugs during the study.
19
Our results also highlight the success of the collabo-
rative capacity-building SIDI projects: these sites are
highly suitable and ready for HIV prevention research
and programming. Both sites added staff and were
provided broad research training, and these new skills
were immediately applied in a rigorous clinical research
study. Dealing with local ethics committees and commu-
nity stakeholders, recruiting and enrolling potentially
higher risk women, administering informed consent,
bringing participants back for regular study visits, giving
ongoing risk reduction and HIV counselling and making
referrals for continued healthcare, all within the context
of Good Clinical Practice, mimicked future prevention
trials. At the conclusion of its study, JOSHA in Bloem-
fontein was selected to implement an oral HIV prophy-
laxis trial. The Aurum Institute in Rustenburg is currently
conducting a trial of a vaginal microbicide, along with
other behavioural HIV studies. The national research
capacity has been boosted and diffused to new sites
Table 4 HIV incidence among women in the prospective
study at the Bloemfontein and Rustenburg sites
Bloemfontein Rustenburg
Number with HIV
test result during
follow-up
391 194
Conﬁrmed HIV
seroconversions
92
Person-years of
follow-up
164.4 67.1
Incidence rate*
(95% CIy)
5.5 (2.5 to 10.4) 3.0 (0.4 to 10.8)
*Per 100 person-years.
yExact CI.
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